Slide background We deliver actionable insights based on deep
life science domain knowledge and in-depth analysis
to drive pipeline and portfolio value

SmartAnalyst provides comprehensive, integrated solutions based on our deep understanding of the science, the market, and the key business decisions that our clients face.  We deploy agile, cross-functional project teams that are responsive to client needs.

Our experienced team of experts use our proprietary strategic frameworks to help biopharma companies make key decisions at the Disease, Asset, and Portfolio levels, including:

Disease Strategy
  • Strategic Disease Prioritization: Prioritization of diseases within a franchise area based on scientific attractiveness, commercial attractiveness, and innovation attractiveness
  • Discovery and Commercial Alignment: Determine what early programs to pursue; and gain alignment between Discovery and Commercial
  • Integrated Disease Strategy: 5-10 year future disease strategy perspective to support investment decisions, including key targets, MOAs, treatment evolution, and internal/external asset mix
Asset Strategy
  • Opportunity Prioritization: Evaluate and drive prioritization decisions across multiple granular patient segment opportunities for early assets or for lifecycle planning
  • Value Proposition: Clinical and Payor benefit thresholds and evidence required for success; help drive asset go/no-go decisions
  • Label and Pre-Positioning and Messaging: Simulating the label as value driver; developing asset pre-positioning
  • Commercial Assessment, Forecasting and Valuation: Commercial and TPP assessment to understand forecast drivers, forecast range, and rNPV
  • Patient Journey Mapping: Understand the patient journey to identify leverage points and influencers
  • Differentiation: Target product profile (TPP) development and testing; identification and validation of meaningful differentiators
  • Regional Priorities: Identification of asset strategy for a specific country or group of countries; unique considerations in emerging markets
  • Health economics: Disease modeling for scenario planning, economic justification, and real world evidence
Portfolio Strategy
  • Portfolio Tradeoffs and Optimization: Program correlations and risk-return tradeoffs to optimize portfolio value
Business Development Strategy
  • Filling Portfolio Gaps Through BD&L: Screening, prioritization, and in-depth commercial assessment and independent valuation of opportunities

Our mission is to deliver customized and insightful recommendations to help clients make superior business decisions. As a strong and reliable partner, our commitment is to consistently deliver robust solutions to meet our client's business objectives and enhance value.  We collaborate with honesty, integrity, and respect. We take pride in building personal, lasting relationships with our clients.

At SmartAnalyst, we aim to make a difference.
  • 100% focused on life science and have completed more than 1,000 engagements in the past 5 years
  • Successful track record and experience with the majority of the top biopharma companies as well as numerous smaller biotech/emerging companies
  • Develop and utilize sophisticated strategic frameworks and proprietary platforms 
  • Global footprint covering G7 and key emerging markets (BRICTMK)
  • Global scale with >125 professional staff including consultants, analysts, clinicians, scientists, and financial modelers 
  • In-depth expertise in key therapeutic areas including Oncology, Cardiovascular and Metabolics, Neuroscience, Immunology, Hematology and Rare Diseases
  • Expertise in specialized areas including gene therapy, biomarkers, vaccines and biosimilars
  • Global primary research capabilities with a large network of KOLs, prescribers, and payors